Adagene (FRA:978) Total Liabilities: €36.65 Mil (As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.78
GF Value €11.92
! 5 Warning Signs
View Full Analysis

What is Adagene Total Liabilities?

Adagene FRA:978 -5.97% 42 Total Liabilities is €36.65 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.92. The stock has 5 warning signs investors should review.

Adagene's Total Liabilities for the quarter that ended in Dec. 2025 was €36.65 Mil.

Adagene's quarterly Total Liabilities declined from Dec. 2024 (€37.00 Mil) to Jun. 2025 (€24.80 Mil) but then increased from Jun. 2025 (€24.80 Mil) to Dec. 2025 (€36.65 Mil).

Adagene's annual Total Liabilities declined from Dec. 2023 (€41.42 Mil) to Dec. 2024 (€37.00 Mil) and declined from Dec. 2024 (€37.00 Mil) to Dec. 2025 (€36.65 Mil).

Adagene Total Liabilities Historical Data

* Premium members only.

The historical data trend for Adagene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Total Liabilities Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 29.16 65.43 41.42 37.00 36.65

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.42 41.05 37.00 24.80 36.65
FRA:978
42GF Score
Adagene Inc FRA:978
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adagene's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.497+(1.018+14.134
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=36.65

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=66.837-30.189
=36.65

Adagene's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=21.497+(1.018+14.134
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=36.65

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=66.837-30.189
=36.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €36.65 Mil mean?
Adagene (FRA:978) has a Total Liabilities of €36.65 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adagene and its competitors.
Is Adagene's Total Liabilities too high?
Adagene's current Total Liabilities is €36.65 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Total Liabilities compare to RNAC and LYEL?
Adagene's Total Liabilities of €36.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adagene and its competitors. Adagene's current Total Liabilities is €36.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Total Liabilities of €36.65 Mil. The stock's GF Value™ is €11.92, compared to a current price of €3.78 — trading 68.3% below its estimated fair value. The current Total Liabilities is €36.65 Mil. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Adagene (FRA:978), the current Total Liabilities is €36.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.78 is trading 68.3% below its estimated GF Value™ of €11.92.

Key valuation signals for FRA:978:

  • Total Liabilities: €36.65 Mil
  • GF Value™: €11.92 vs. price of €3.78 (68.3% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€11.92
GF Value